Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05365048 · ClinicalTrials.gov registry record · NA
Provider Recommendation and HPV Vaccination
A NA study of Human Papillomavirus, sponsored by Kaiser Permanente.
- Recruiting
- Registry status
- NA
- Development phase
- 301,201
- Enrollment target
- 1
- Study location
NCT05365048 is a NA study of Human Papillomavirus that is actively recruiting participants, run by Kaiser Permanente. The registered enrollment target is 301,201 participants, above the 982-participant average among 12 other Human Papillomavirus trials with a reported enrollment target (30572% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05365048, a NA study of Human Papillomavirus, is actively recruiting participants, sponsored by Kaiser Permanente.
- RECRUITING
- Registry status
- NA
- Development phase
- 301,201 participants
- Enrollment target
- 1
- Study location
Study Summary
In the United State, there are millions of US teens who are not vaccinated against the human papillomavirus (HPV) putting them at risk of getting HPV-related cancers. Although there are clinical guidelines recommending the HPV vaccine and interventions encouraging parents to vaccinate their children to prevent HPV-related cancers, the vaccination rate for teens remains low according to a 2018 national survey. Survey data shows that HPV vaccine complete series coverage for teens aged 13-15 years was 50%, far below the 80% target of Healthy People 2020. Receiving a strong provider recommendation is the most powerful strategy for improving HPV vaccine rates. Yet, little is known about how to include provider recommendations and other important factors into an intervention to improve the HPV vaccination rates. Studies show there are provider, patient and system-level barriers in the initiation and completion of HPV vaccine series among 9-12 years old children. Barriers to the HPV vaccine also differ across demographic subgroups, communities, and clinics. Interventions that address only one component are not responsive to site barriers and as effective as one that addresses multiple components and site-specific barriers. This study uses a 3-arm cluster randomized controlled trial (RCT) to compare three implementation strategies to improve provider recommendations on the HPV vaccine. Two of the implementation strategies (local-tailored and prescribed strategy) utilize a multilevel approach. The three implementation strategies of interest are (1) a "local-tailored" implementation strategy, co-designed with local care teams to address local barriers and contexts (2) A "prescribed" strategy, most commonly used by health systems, that involves pre-specified interventions addressing pre-selected vaccination barriers and (3) usual standard of care where there are no research-led activities. We will use surveys, interviews, and electronic health records to evaluate the three imp
Conditions Studied
Interventions
- OTHER Local Tailoring implementation strategy
- OTHER Prescribed Strategy
Study Locations (1)
California
- Kaiser Permanente Southern California - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301,201 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05365048
The ClinicalTrials.gov registry entry for NCT05365048 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 301,201 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 982-participant average among 12 other Human Papillomavirus trials with a reported enrollment target (30572% higher). The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Papillomavirus appearing as the primary indexed condition, and to 2 interventions - of which Local Tailoring implementation strategy is the first listed.
NCT05365048 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05365048 about?
NCT05365048 is a clinical study titled "Provider Recommendation and HPV Vaccination". In the United State, there are millions of US teens who are not vaccinated against the human papillomavirus (HPV) putting them at risk of getting HPV-related cancers. Although there are clinical guidelines recommending the HPV vaccine and interventions encouraging parents to vaccinate their children...
What is the current status of trial NCT05365048?
This trial is currently recruiting. It is a NA study. The enrollment target is 301,201 participants. The study started on 2022-03-21. Estimated completion is 2026-06-30.
What conditions does trial NCT05365048 study?
This clinical trial studies the following conditions: Human Papillomavirus.
What interventions are being tested in trial NCT05365048?
The interventions under investigation include: Local Tailoring implementation strategy (OTHER), Prescribed Strategy (OTHER).
Who is sponsoring clinical trial NCT05365048?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05365048 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Video to Promote HPV Vaccination
COMPLETED · NA
-
txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men
COMPLETED · NA
-
Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
RECRUITING
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
RECRUITING
-
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.